Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$3.15 – $4.75
11% from low
Exchange
OTC Link
OS
JCR PHARMACEUTICALS CO
No one on the platform currently holds JCRRF.
No tracked institution reports a position in JCRRF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2027-03-31 | $10.0000 | |
| 2026-09-30 | $10.0000 | |
| 2026-03-31 | $10.0000 | 2026-06-24 |
| 2025-09-30 | $10.0000 | 2025-12-05 |
| 2025-03-31 | $10.0000 | 2025-06-26 |
| 2024-09-30 | $10.0000 | 2024-12-06 |
| 2024-03-28 | $10.0000 | 2024-06-27 |
| 2023-09-29 | $10.0000 | 2023-12-08 |
No one on the platform has traded JCRRF yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $44.5B | +13.6% | $3.96 | $2.99–$4.36 | 0.8× | 1 |
| 2028 | $42.3B | -4.8% | $3.17 | $2.39–$3.49 | 1.0× | 1 |
| 2029 | $43.3B | +2.4% | $11.30 | $8.53–$12.44 | 0.3× | 1 |
| 2030 | $46.3B | +6.8% | $19.83 | $14.97–$21.83 | 0.2× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $-0.07 | $-0.10 | -38.8% |
| 2026-05-13 | $-0.04 | $0.02 | +153.9% |
| 2026-01-28 | $-0.01 | $0.00 | +125.1% |
| 2025-10-30 | $0.14 | $0.13 | -9.2% |
| 2025-07-30 | $0.03 | $-0.03 | -202.8% |
| 2025-05-13 | $-0.36 | $-0.23 | +37.1% |
| 2025-01-31 | $0.07 | $0.01 | -92.0% |
| 2024-10-30 | $0.10 |
| $-0.05 |
| -152.0% |
| +0.00% |
| $547M |
| — |
| GLASFGlass House Brands Inc. | $10.79 | -8.64% | $852M | — |
| GSGTFGenSight Biologics S.A. | $0.09 | +0.00% | $15M | — |
Source: Financial Modeling Prep · peers by sector/industry